NEW YORK, Sept 21 (Reuters) - Two large drug makers, Eli Lilly and Co and Daiichi Sankyo Co Ltd, face a critical U.S. decision this week on their shared blood-clot preventer that could dramatically boost their bottom lines.
NEW YORK, Sept 21 (Reuters) - Two large drug makers, Eli Lilly and Co and Daiichi Sankyo Co Ltd, face a critical U.S. decision this week on their shared blood-clot preventer that could dramatically boost their bottom lines.
